CPT 50825 — Continent Diversion, Neobladder Construction (Open)

Overview and Clinical Description

CPT 50825 describes an open continent urinary diversion in which a surgeon uses any segment of the small intestine (most commonly the ileum), the large intestine (sigmoid, cecum), or a combination of both to construct an orthotopic neobladder — a low-pressure, continent internal reservoir that is anastomosed directly to the urethra, allowing the patient to void volitionally. This code specifically covers the diversion/reconstruction component as a procedure in its own right and is distinct from codes that bundle the cystectomy with the diversion in a single operative description (see 51595 and 51596).

The distinguishing feature of 50825 is that it captures the continent reconstruction when the cystectomy and diversion are either staged separately or when coding conventions require the diversion to be identified independently. In common clinical practice, a surgeon may perform a radical cystectomy at one operative session and the neobladder construction either concurrently (billed as 51595/51596) or, less commonly, as a staged procedure with 50825 used to capture the diversion.

Because this code encompasses any open technique, it applies to a broad family of neobladder platforms including but not limited to the Studer orthotopic neobladder (using a detubularized ileal segment with an afferent limb), the Hautmann W-pouch or M-pouch, the T-pouch (incorporating an anti-reflux valve), the Le Bag (ileocolonic reservoir), and variations using the right colon or cecum. The coding language makes no distinction between these configurations — the critical criteria are (1) open surgical approach, (2) use of intestinal segment(s), (3) continent reservoir design, and (4) orthotopic placement with urethral anastomosis.

Anatomy and Surgical Context

The neobladder replaces the native bladder following radical cystectomy for muscle-invasive or high-risk urothelial carcinoma. After the bladder is resected (and in males, typically with the prostate; in females, with the anterior vaginal wall and sometimes the uterus/ovaries), a 40-60 cm segment of ileum (approximately 20-25 cm proximal to the ileocecal valve to preserve vitamin B12 absorption) is isolated with its mesentery intact to ensure blood supply. The segment is detubularized — opened along its antimesenteric border — and then folded and sutured into a spherical reservoir. This configuration reduces the amplitude of intestinal peristaltic contractions, creating a low-pressure pouch that reduces the risk of upper tract damage from reflux and allows controlled voiding.

The ureters are implanted directly into the pouch (using either a simple direct anastomosis or an anti-reflux Le Duc or serous-lined extramural tunnel technique), and the most dependent portion of the neobladder is anastomosed to the retained urethra using absorbable interrupted sutures. Bowel continuity is re-established with either a hand-sewn or stapled end-to-end or side-to-side anastomosis.

CPT Coding Details

Work RVU (wRVU): Approximately 51.72 (verify against the current CMS Physician Fee Schedule for the applicable year, as RVU values are updated annually).

This is among the highest-wRVU urology procedures, reflecting the extraordinary technical demand, operative duration (typically 4-7 hours), significant intraoperative decision-making, and the management of complications inherent to major pelvic extirpative surgery with bowel reconstruction.

Global Period: 90 days. All post-operative care is included in the surgical fee for 90 days from the date of service unless a modifier applies.

Assistant Surgeon: Yes — payable. The complexity and duration of this procedure, combined with the need for simultaneous pelvic and intestinal operative fields, consistently supports the use of an assistant surgeon. Modifier -80 (Assistant Surgeon) or -82 (Assistant Surgeon when qualified resident not available) applies.

Teaching Physician/Resident Rules: When performed in a teaching facility, the teaching physician must be physically present during the key and critical portions of the procedure.

Bilateral Indicator: 0 (procedure is not subject to bilateral modifier).

Multiple Procedure Indicator: 2. If performed with other procedures in the same operative session (e.g., lymphadenectomy), standard multiple procedure reductions apply. The second procedure is typically reimbursed at 50%.

Modifier Applicability:

-22 (Increased Procedural Services) — May be appended when a significantly greater-than-usual service is required, such as when there is extensive scarring from prior pelvic radiation, previous bowel or bladder surgery, or exceptionally complex anatomy. Requires supporting operative report documentation.
-51 (Multiple Procedures) — Used when 50825 is billed alongside other distinct procedures on the same day.
-62 (Two Surgeons) — Applicable when two surgeons of different specialties each perform distinct components during the same operation (e.g., a urologist and a colorectal surgeon operating simultaneously).
-80/-82 — As discussed, for assistant surgeon billing.

Associated ICD-10-CM Diagnoses

These are the most clinically relevant diagnoses associated with the operative indication for CPT 50825. HCC assignments reflect the CMS HCC Risk Adjustment Model v24 (the most widely operationalized model) and v28 (the updated model phased in beginning FY2024). HCC coding is critical for accurate risk stratification in Medicare Advantage and value-based care programs.

C67.0 — Malignant Neoplasm of Trigone of Bladder

The trigone, located at the base of the bladder between the ureteric orifices and the urethral opening, is a common site for urothelial carcinoma and is frequently involved in muscle-invasive disease. When the tumor’s primary location is documented as the trigone, this code is used.

HCC v24: HCC 11 — Colorectal, Bladder, and Other Cancers HCC v28: HCC 17 — Lung and Other Severe Cancers (note: v28 reclassified several bladder cancer codes into higher-weighted categories) RAF Additive: Yes — this diagnosis contributes meaningfully to the patient’s risk adjustment factor score.

C67.1 — Malignant Neoplasm of Dome of Bladder

The dome is a frequent site of non-invasive (pTa, pT1) tumors that may progress to muscle-invasive disease. This code is used when the pathology report or operative documentation specifies the dome as the primary tumor site.